Poolbeg Pharma PLC (id:4095 POLB)

7.75 GBP

Opening hours: 08:00 - 16:30 (GMT Standard Time: 11/22/2024 5:37:28 PM)

Exchange closed, opens in 2 days 14 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Poolbeg Pharma PLC

Market Capitalization 41.93M

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.